Verseau Therapeutics
Auburndale, US · Founded 2017 · Delaware corporation · 6 employees on LinkedIn · 2 known investors
Find your way into Verseau Therapeutics
400 people in our graph share verified history with the Verseau Therapeutics team — schools, employers, funds. One of them is your warm intro.
Anthony Philippakisunlockedknows Tatiana Novobrantseva · together at Harvard Medical School (overlapped)
knows the team · via FairJourney Biologics
knows the team · via Moderna
knows the team · via Columbia University
knows the team · via Jounce Therapeutics
knows the team · via University of Cologne
Verseau Therapeutics discovers and develops macrophage-targeting monoclonal antibodies to enhance anti-tumor immune responses in cancer patients. The company uses a patient-based discovery engine to identify novel targets for immunotherapy, focusing on treating solid tumors where macrophages are prevalent.
Founders & leadership
Verseau Therapeutics was founded in 2017 by Bob Langer, Dan Anderson, Tatiana Novobrantseva, and Igor Feldman.
BL
Bob LangerCo-founder
DA
TN
Tatiana NovobrantsevainTatiana Novobrantseva has worked across drug development modalities including protein and nucleic acid therapeutics, with experience in immunology, inflammation, and immuno-oncology programs. She has held operational and advisory roles at biotech startups focused on bringing novel medicines to patients.
IF
Igor FeldmaninIgor Feldman is a computational biologist who co-founded Verseau Therapeutics and previously led clinical and translational bioinformatics at Moderna, where he supported oncology programs including personalized cancer vaccines using multi-omics data. He has also advised AI-focused biotech companies on translational strategy and computational biology platform development.
WC
Walter CaponeExecutive
CB
Christine BuntinChief Executive Officer, Chairman of the Board, Senior Advisor2017–2021
Board
JC
Jong ChangBoard director
Investors · 2
Reported raises · per SEC filings
Form D private placements$4.3M disclosed across 1 round · 2017
▶$4.3MraisedMar 2017 · 5 investors · Other Health CareRule 506(b)
▶$4.3MraisedMar 2017 · 5 investors · Other Health Care
Rule 506(b)Officers, directors & promoters on the filing
- Daniel AndersonExecutive Officer, Director, Promoter
- Walter CaponeExecutive Officer
- Robert LangerDirector, Promoter
- Jong ChangDirector
- Christine BuntExecutive Officer, Director
- Offering amount
- $11.4M
- Amount sold
- $4.3M
- First sale
- Mar 2017
- Incorporated
- Corporation, Delaware, 2017
- Federal exemptions
- 06b
Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.
Competitors · 4
by search overlap
Veratx6 shared keywordsVera Therapeutics develops medicines targeting autoimmune-driven kidney diseases, with a focus on reducing the need for dialysis or transplant. The company was founded by a physician and operates as a clinical-stage biotech with a patient-centered approach to drug development.
Vivace Therapeutics3 shared keywordsVivace Therapeutics is an oncology-focused drug discovery and development company creating small-molecule inhibitors targeting the Hippo-YAP pathway to treat cancers including mesothelioma, meningioma, and various other tumor types. The company adopts a capital-efficient approach to advance novel cancer therapeutics, with potential applications also in fibrotic disease.
Edgewise Therapeutics3 shared keywordsEdgewise Therapeutics develops precision therapeutics for serious cardiovascular disease.
Solu3 shared keywordsSolu Therapeutics is a clinical-stage biotech developing a class of antibody therapeutics that link bifunctional small molecules to proprietary effector antibodies (its CyTAC and TicTAC platforms) to reach cell surface targets like GPCRs and ion channels. Its pipeline targets oncology, immunology and inflammation, and pain, with a lead program in Phase 1 trials for chronic myelomonocytic leukemia.
Companies competing with Verseau Therapeutics for the same Google search keywords, organic and paid, via search-intersection analysis.
In the news
Frequently asked questions
- What does Verseau Therapeutics do?
- Verseau Therapeutics discovers and develops macrophage-targeting monoclonal antibodies to enhance anti-tumor immune responses in cancer patients. The company uses a patient-based discovery engine to identify novel targets for immunotherapy, focusing on treating solid tumors where macrophages are prevalent.
- Who founded Verseau Therapeutics?
- Verseau Therapeutics was founded by Bob Langer, Dan Anderson, Tatiana Novobrantseva, Igor Feldman in 2017.
- Who are Verseau Therapeutics's investors?
- Verseau Therapeutics's investors include 20/20 HealthCare Partners LLC, Highlight Capital.
- How much funding has Verseau Therapeutics raised?
- Verseau Therapeutics has disclosed $4.3M raised across 1 round.
- Where is Verseau Therapeutics headquartered?
- Verseau Therapeutics is headquartered in Auburndale, US.